Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
O-PCE is considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. Compulsive redosing is commonly reported, particularly due to its potency and stimulating nature.
Cravings and withdrawal effects may occur when a person suddenly stops usage after addiction has developed, though the severity of physical dependence appears less pronounced than the psychological component.
The exact toxic dosage is unknown due to O-PCE's very limited history of human usage and absence of scientific study on its toxicity.
Repeated and excessive use over extended periods may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency, urgency, pressure, pelvic and bladder pain, hematuria, and incontinence; occasional use appears to carry minimal risk.
Mania is listed among potential cognitive effects at higher doses. As with other dissociatives, O-PCE may carry some risk of adverse psychological reactions including delusions and psychosis, particularly at higher doses or in predisposed individuals.
O-PCE emerged as part of the wave of novel arylcyclohexylamine designer drugs that appeared on the online research chemical market following the decline in MXE availability. The compound was specifically developed and marketed as a functional replacement for MXE and other dissociatives that had…
Classified as a controlled substance under Schedule I (List 4). Despite this scheduling, limited exceptions exist for research purposes and restricted therapeutic applications.
Not currently scheduled under Dutch drug legislation. Available for purchase as a research chemical through legitimate vendors.
Controlled under the Misuse of Drugs Act 1971. As an N-alkyl derivative of 2-amino-2-phenylcyclohexanone, it falls under the arylcyclohexylamine generic clause introduced by Statutory Instrument 2013/239, which became effective on February 26, 2013. Possession, production, supply, and importation are prohibited.
Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Manufacturing and importing for market distribution, administering to others, and commercial trading are criminally punishable offenses. Personal possession remains illegal but is not subject to criminal penalties.
Explicitly named as a controlled substance under Verzeichnis E of the Swiss narcotics regulations.
11 sources cited
